Target expression details
Target General Information | |||||
---|---|---|---|---|---|
Target ID | T55959 | ||||
Target Name | Dopamine transporter | ||||
Synonyms | DA transporter; DAT; Dopamine transporter; SLC6A3 | ||||
Target Type | Successful | ||||
Gene Name | SLC6A3 | ||||
Biochemical Class | Neurotransmitter:sodium symporter | ||||
UniProt ID | SC6A3_HUMAN | ||||
Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals | |||||
Disease | Parkinson's disease | ||||
Example drug | Ioflupane i-123 | Approved | [531783], [1572592] | ||
Tissue | Substantia nigra tissue | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -3.08 Z-score: -1.99 P-value: 1.08E-03 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
Disease | Depression | ||||
Example drug | GSK-1360707 | Phase 1 | [523095], [1572592] | ||
Tissue | Pre-frontal cortex | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: 4.04E-03 Z-score: 0.02 P-value: 4.17E-01 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
Target Gene Expression Profiles in Other Tissues of Healthy Individuals | |||||
Reference | |||||
Ref 523095 | ClinicalTrials.gov (NCT01153802) An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy,Pharmacokinetics and Safety of Single Oral Dosesof GSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.